These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33429902)

  • 1. Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs.
    Benavent E; Morata L; Escrihuela-Vidal F; Reynaga EA; Soldevila L; Albiach L; Pedro-Botet ML; Padullés A; Soriano A; Murillo O
    Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33429902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Tolerability of More than Six Days of Tedizolid Treatment.
    Mensa Vendrell M; Tasias Pitarch M; Salavert Lletí M; Calabuig Muñoz E; Morata Ruiz L; Castells Lao G; López Suñé E; Mensa Pueyo J; Oltra Sempere MR; Pedro-Botet Montoya ML; Isernia V; Reynaga Sosa EA; Moreno Nuñez L; Pasquau Liaño J; Sequera Arquelladas S; Yuste Ara JR; Soriano Viladomiu A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32312777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting.
    Abad L; Tafani V; Tasse J; Josse J; Chidiac C; Lustig S; Ferry T; Diot A; Laurent F; Valour F
    J Antimicrob Chemother; 2019 Mar; 74(3):625-632. PubMed ID: 30517641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
    Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
    J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
    Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of tedizolid for the treatment of MRSA infections.
    Hall RG; Smith WJ; Putnam WC; Pass SE
    Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
    Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
    J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections.
    Delpech P; ALeryan M; Jones B; Gemmell C; Lang S
    Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of tedizolid as oral treatment for bone and joint infections.
    Miller LG; Flores EA; Launer B; Lee P; Kalkat P; Derrah K; Agrawal S; Schwartz M; Steele G; Kim T; Kuvhenguhwa MS
    Microbiol Spectr; 2023 Sep; 11(5):e0128223. PubMed ID: 37750695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of tedizolid in skin and soft tissue infections.
    Bouza E; Muñoz P; Burillo A
    Curr Opin Infect Dis; 2018 Apr; 31(2):131-140. PubMed ID: 29346119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of tedizolid and other comparator drugs in methicillin-resistant Staphylococcus aureus isolates in skin and soft tissue infections in seven Colombian hospitals.
    Leal AL; Ovalle MV; Cortés JA; Montañes AM; De la Rosa ZR; Rodríguez JY; Gualtero S; Ariza B; Sussman O; Torres MDP
    Biomedica; 2018 Dec; 38(4):507-513. PubMed ID: 30653864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
    Rybak JM; Marx K; Martin CA
    Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections.
    Littorin C; Hellmark B; Nilsdotter-Augustinsson Å; Söderquist B
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1549-1552. PubMed ID: 28326447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections.
    Hall RG; Michaels HN
    Infect Drug Resist; 2015; 8():75-82. PubMed ID: 25960671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials.
    Moran GJ; De Anda C; Das AF; Green S; Mehra P; Prokocimer P
    Infect Dis Ther; 2018 Dec; 7(4):509-522. PubMed ID: 30242736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.
    Lodise TP; Bidell MR; Flanagan SD; Zasowski EJ; Minassian SL; Prokocimer P
    J Antimicrob Chemother; 2016 Sep; 71(9):2553-8. PubMed ID: 27317442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.
    Werth BJ
    J Antimicrob Chemother; 2017 May; 72(5):1410-1414. PubMed ID: 28158617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.